WHO ICTRP trial
Effect of Tolvaptan on hemodynamic of congestive heart failure.
JPRN-UMIN000012170 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000012170 |
|---|---|
| Public title | Effect of Tolvaptan on hemodynamic of congestive heart failure. |
| Scientific title | Effect of Tolvaptan on hemodynamic of congestive heart failure. - Effect of Tolvaptan on hemodynamic of congestive heart failure. |
| Primary sponsor | Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Congestive heart failure |
| Interventions | Tolvaptan group Tolvaptan 7.5mg/day and Fulosemide 10mg/day are administered for 7days. If not effective, Tolvaptan is administered up to 15mg/day. Control group Fulosemide in administered for 7days. |
| Registration date | Oct 31, 2013 |
| Target size | 60 |
| Secondary IDs | G23045 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: